For instance, BVD-523, also named ulixertinib [211,219], has advanced to clinical trials in cases of advanced-stage malignant tumors, including B-RAF-mutated colorectal cancer, melanoma, non-small cell lung cancer, N-RAS-mutated melanoma, acute myelogenous leukemia, myelodysplastic syndromes, and MEK- and ERK-mutated cancers (NCT01781429, NCT02296242, NCT02608229). This evidence concerns the gene NRAS and cancer.